A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Public ClinicalTrials.gov record NCT05239728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Study identification
- NCT ID
- NCT05239728
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 1,800 participants
Conditions and interventions
Conditions
Interventions
- Belzutifan Drug
- Pembrolizumab Biological
- Placebo Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2022
- Primary completion
- Oct 27, 2026
- Completion
- Sep 27, 2029
- Last update posted
- May 3, 2026
2022 – 2029
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix ( Site 3554) | Phoenix | Arizona | 85054 | — |
| City of Hope Comprehensive Cancer Center ( Site 3567) | Duarte | California | 91010 | — |
| Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516) | La Jolla | California | 92093 | — |
| UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520) | Los Angeles | California | 90095 | — |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518) | Orange | California | 92868 | — |
| Stanford Cancer Center ( Site 3523) | Palo Alto | California | 94304 | — |
| University of Colorado Anschutz Medical Campus ( Site 3514) | Aurora | Colorado | 80045 | — |
| Intermountain Health St. Mary's Regional Hospital ( Site 3562) | Grand Junction | Colorado | 81501 | — |
| Georgetown University Medical Center ( Site 3534) | Washington D.C. | District of Columbia | 20007 | — |
| University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 3517) | Miami | Florida | 33136 | — |
| Moffitt Cancer Center ( Site 3540) | Tampa | Florida | 33612 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515) | Marietta | Georgia | 30060 | — |
| Parkview Research Center at Parkview Regional Medical Center ( Site 3526) | Fort Wayne | Indiana | 46845 | — |
| Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549) | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital ( Site 3571) | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572) | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute-GU ( Site 3505) | Boston | Massachusetts | 02215 | — |
| Cancer and Hematology Centers of Western Michigan ( Site 3502) | Grand Rapids | Michigan | 49503 | — |
| Washington University-Internal Medicine/Oncology ( Site 3531) | St Louis | Missouri | 63110 | — |
| St. Vincent Frontier Cancer Center-Research ( Site 3506) | Billings | Montana | 59102 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550) | Omaha | Nebraska | 68130 | — |
| Englewood Hospital and Medical Center ( Site 3557) | Englewood | New Jersey | 07631 | — |
| Rutgers Cancer Institute of New Jersey ( Site 3541) | New Brunswick | New Jersey | 08903 | — |
| Monter Cancer Center ( Site 3560) | Lake Success | New York | 11042 | — |
| Icahn School of Medicine at Mount Sinai ( Site 3539) | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center ( Site 3568) | New York | New York | 10065 | — |
| University of Rochester Medical Center ( Site 3528) | Rochester | New York | 14642 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3507) | Columbus | Ohio | 43210 | — |
| MidLantic urology ( Site 3501) | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Fox Chase Cancer Center-GU Oncology ( Site 3535) | Philadelphia | Pennsylvania | 19111 | — |
| Sanford Cancer Center ( Site 3551) | Sioux Falls | South Dakota | 57104 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 3522) | Germantown | Tennessee | 38138 | — |
| Urology Associates ( Site 3512) | Nashville | Tennessee | 37209 | — |
| UT Southwestern Medical Center ( Site 3529) | Dallas | Texas | 75390 | — |
| University of Texas MD Anderson Cancer Center-Urology ( Site 3569) | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute ( Site 3525) | Fairfax | Virginia | 22031 | — |
| Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 3524) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 248 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05239728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05239728 live on ClinicalTrials.gov.